Sep 12, 2020

The value of healthcare data to empower tomorrow’s patients

Artificial intelligence
healthcare data
participatients
patient choice
Robin Stern
3 min
The value of healthcare data to empower tomorrow’s patients
Robin Stern, Executive Chair at Future Perfect, explains how healthcare data can empower patient choice...

The term ‘participatient’ is about empowering patients to take part in their own healthcare, and I don’t think this has ever mattered more. With an ageing population, increases in the number of those with complex long-term health conditions, and growing evidence of the lasting effects of the coronavirus, - it’s safe to say that better-informed patients will have a smoother road to recovery. It also means an easier process for clinicians if less time is spent struggling with less-informed and more advice-dependent patients. But what is the missing piece of the puzzle when it comes to turning the idea into reality?

The use of apps and remote care solutions is on the rise, and Spring 2020 saw the rapid adoption of these practices. I am of the view that to really understand a patient’s data sufficiently to offer effective, accurate and actionable advice requires AI-enabled systems. There are just far too many data points to link into burgeoning evidence bases for any other stratagem. But as the healthcare system takes stock of the impact of the pandemic, what will be left is the realisation that these solutions aren’t just helpful in times of crisis; they’re essential for the future of how we deliver healthcare.

The benefits of AI-enabled patient participation 

 How would this idealised system of healthcare work? Understanding that means understanding the benefits to be gained from people playing an active part in managing their health – improved lifestyles and health maintenance, more accurate self-care, and less information dependency upon clinicians.

Then, when people ‘enter the system’, clinicians also benefit from diagnostic and treatment decisions aided by AI-driven guidance, like having a ‘second pair of eyes’ to support them – creating clear pathways and aiding the dialogue between clinicians and patients. After diagnosis, ‘participatients’ can access personalised, intelligence-driven digital health services via apps and online systems, cutting down on calls to doctors and saving time. ‘Participatients’ with complex co-morbidities will also have better outcomes, due to the intelligence-driven pathways that inform their treatment. 

If clinicians can use AI-driven solutions to see the link between the actual clinical outcomes people experience and their genomic attributes, diagnostic and interventional procedures and prescribed drugs - better pathways can be established and effectively communicated with the patient, leading to better outcomes.

A patient that is well-informed, from clear pathways set out by clinicians, is far more likely to take an active role in their own treatment. It takes a partnership between the two, enabled by AI, to make the best outcomes a reality.

Clarity of communication

Communication between clinician and patient is vital to making this happen, particularly in the management of long-term health conditions, and in a world where remote care is now a ‘must-have’. A lack of face-to-face contact needn’t be a barrier to good communication anymore.

Clarity of communication becomes stronger when all the data about a patient’s care - across major acute diagnostic hubs, local acute treatments, community and social care support and GPs - is easily accessible from a single source to clinician and patient alike. This is also far more valuable when clinicians and patients have access to AI to interpret that data. It’s that combination of AI and the human touch that lies in the future for the NHS.

The AI-enabled participatient

AI-enabled digital solutions are the key to unlocking the true value of active patient participation. The concept of patients taking more of a role in managing themselves has been in our sights for a long time. If both patient and clinician have access to their data across multiple settings, that is a good start. If the clinician can use AI-enabled solutions to interpret the data and make recommendations, that elevates it to the next level, and then we can reach the true potential of the ‘participatient’.

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

NHS
Cancer
immunotherapy
MachineLearning
2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article